| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
111,250,000 |
| Market
Cap: |
230.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.05 - $5.04 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Invivyd is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious disease. Co. is developing its primary product candidate, adintrevimab, for the prevention and treatment of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Adintrevimab is designed to be a neutralizing antibody for both the prevention and treatment of COVID-19. Co. is also evaluating additional neutralizing antibodies targeting the receptor binding domain, as well as other subdomains within the spike protein for COVID-19.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,858,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$12,230,840 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
5,000,000 |
5,000,000 |
5,000,000 |
| Total Sell Value |
$0 |
$19,750,000 |
$19,750,000 |
$19,750,000 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Adimab, Llc |
|
– – • |
2024-01-19 |
4 |
S |
$3.95 |
$19,750,000 |
D/D |
(5,000,000) |
21,687,906 |
|
56% |
|
| Cotter Sara |
|
– • – |
2023-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
10% |
|
| Schmidt Peter |
Chief Medical OfficerOfficer |
• – – |
2022-12-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,971 |
|
-39% |
|
| Hering David |
Chief Executive Officer |
• • – |
2022-09-01 |
4 |
B |
$4.52 |
$36,160 |
D/D |
8,000 |
8,000 |
2.81 |
-52% |
|
| M28 Capital Management Lp |
See Footnote 5 |
– – – |
2022-08-19 |
4 |
B |
$4.62 |
$2,700,164 |
I/I |
584,451 |
9,248,250 |
0.01 |
-64% |
|
| M28 Capital Management Lp |
See Footnote 5 |
– – – |
2022-08-18 |
4 |
B |
$4.31 |
$5,454,516 |
I/I |
1,265,549 |
8,663,799 |
0.01 |
-67% |
|
| M28 Capital Management Lp |
See Footnote 5 |
– – – |
2022-08-17 |
4 |
B |
$4.04 |
$4,040,000 |
I/I |
1,000,000 |
7,398,250 |
0.01 |
-67% |
|
| Population Health Equity Partners Vii Gp, Llc |
|
– – – |
2022-03-28 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
679,822 |
|
- |
|
| M28 Capital Management Lp |
|
– – – |
2022-03-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,398,250 |
|
5% |
|
| Cox Christopher T |
|
– – – |
2022-03-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
679,822 |
|
5% |
|
| Flint Jonathan A |
|
– – – |
2022-03-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,531,700 |
|
5% |
|
| Adimab, Llc |
See Remarks |
– – • |
2022-03-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,158,089) |
26,687,906 |
|
- |
|
| Andersen Jill |
Chief Legal Officer, Secretary |
• – – |
2021-11-01 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
500 |
|
- |
|
| Andersen Jill |
Chief Legal Officer, Secretary |
• – – |
2021-11-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
2,200 |
|
- |
|
| Gerngross Tillman U. |
Chief Executive Officer |
• • • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
25,860,700 |
27,845,995 |
|
- |
|
| Adimab, Llc |
10% Owner |
– – • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,860,700 |
27,845,995 |
|
- |
|
| Thiel Peter |
10% Owner |
– – • |
2021-08-10 |
4 |
B |
$17.00 |
$33,949,000 |
D/D |
1,997,000 |
11,241,580 |
2.45 |
-53% |
|
| Thiel Peter |
10% Owner |
– – • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,244,580 |
9,244,580 |
|
- |
|
| Mcguire Terrance |
Director |
– • – |
2021-08-10 |
4 |
B |
$17.00 |
$8,500,000 |
I/I |
500,000 |
497,660 |
2.1 |
-53% |
|
| Mcguire Terrance |
Director |
– • – |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,031,700 |
320,160 |
|
- |
|
| Royan Ajay |
Director |
– • • |
2021-08-10 |
4 |
B |
$17.00 |
$33,949,000 |
I/I |
1,997,000 |
11,241,580 |
2.25 |
-53% |
|
| Royan Ajay |
Director |
– • • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
9,244,580 |
9,244,580 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2021-08-10 |
4 |
B |
$17.00 |
$24,990,000 |
I/I |
1,470,000 |
3,390,960 |
1.5 |
-53% |
|
| Green Jeremy |
10% Owner |
– – • |
2021-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,920,960 |
1,920,960 |
|
- |
|
| Hershberger Elham |
Chief Development OfficerOffic |
• – – |
2021-08-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
127,060 |
|
- |
|
28 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (2.82%) 
